XEN496
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Trial Timeline
Aug 17, 2021 → Nov 17, 2023
NCT ID
NCT04912856About XEN496
XEN496 is a phase 3 stage product being developed by Xenon Pharmaceuticals for Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04912856. Target conditions include Epilepsy, Epilepsy in Children, Epilepsy; Seizure.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04912856 | Phase 3 | Terminated |
Competing Products
20 competing products in Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 52 |
| Lacosamide | UCB | Phase 3 | 74 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Zonegran | Eisai | Approved | 85 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| perampanel | Eisai | Approved | 85 |
| E2007 + Placebo | Eisai | Phase 2 | 52 |
| Placebo + Rufinamide | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| Perampanel Oral Tablet | Eisai | Approved | 85 |
| perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Phase 2 | 52 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 85 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 52 |